Pfizer Inc. $PFE Shares Sold by Thurston Springer Miller Herd & Titak Inc.

Thurston Springer Miller Herd & Titak Inc. trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 90.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,434 shares of the biopharmaceutical company’s stock after selling 22,601 shares during the quarter. Thurston Springer Miller Herd & Titak Inc.’s holdings in Pfizer were worth $62,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer during the 1st quarter valued at $27,000. Curio Wealth LLC boosted its stake in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,098 shares in the last quarter. Bayforest Capital Ltd bought a new position in Pfizer in the 1st quarter worth $28,000. Harbor Asset Planning Inc. bought a new position in Pfizer in the 2nd quarter worth approximately $29,000. Finally, Howard Hughes Medical Institute acquired a new position in shares of Pfizer during the second quarter valued at about $30,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock opened at $25.05 on Thursday. The business has a fifty day moving average price of $25.09 and a 200-day moving average price of $24.82. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The firm has a market capitalization of $142.43 billion, a P/E ratio of 14.56 and a beta of 0.46. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date is Friday, January 23rd. Pfizer’s payout ratio is presently 100.00%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on PFE shares. Scotiabank assumed coverage on Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective for the company. The Goldman Sachs Group restated a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a research note on Wednesday, November 5th. UBS Group reissued a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. HSBC restated a “buy” rating and issued a $29.00 price target on shares of Pfizer in a research report on Wednesday, December 10th. Finally, Morgan Stanley dropped their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $28.06.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.